BRPI0509852A - método para a preparação regioespecìfica dos derivados de 42-éster de rapamicina, preparação regioespecìfica do 42-éster de rapamicina, composição, produto, e, kit farmacêutico - Google Patents

método para a preparação regioespecìfica dos derivados de 42-éster de rapamicina, preparação regioespecìfica do 42-éster de rapamicina, composição, produto, e, kit farmacêutico

Info

Publication number
BRPI0509852A
BRPI0509852A BRPI0509852-1A BRPI0509852A BRPI0509852A BR PI0509852 A BRPI0509852 A BR PI0509852A BR PI0509852 A BRPI0509852 A BR PI0509852A BR PI0509852 A BRPI0509852 A BR PI0509852A
Authority
BR
Brazil
Prior art keywords
rapamycin
ester
preparation
regiospecifically
composition
Prior art date
Application number
BRPI0509852-1A
Other languages
English (en)
Inventor
Jianxin Gu
Ping Cai
Mark E Ruppen
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34965235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0509852(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of BRPI0509852A publication Critical patent/BRPI0509852A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)
    • C12N9/20—Triglyceride splitting, e.g. by means of lipase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/18—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing at least two hetero rings condensed among themselves or condensed with a common carbocyclic ring system, e.g. rifamycin
    • C12P17/188—Heterocyclic compound containing in the condensed system at least one hetero ring having nitrogen atoms and oxygen atoms as the only ring heteroatoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

MéTODO PARA A PREPARAçãO REGIOESPECìFICA DOS DERIVADOS DE 42-éSTER DE RAPAMICINA, PREPARAçãO REGIOESPECìFICA DO 42-éSTER DE RAPAMICINA, COMPOSIçãO, PRODUTO, E, KIT FARMACêUTICO. Um método para a síntese regioespecífica dos derivados de 42-éster de rapamicina é descrito. O método envolve a acilação catalisada por lipase de 42-hidróxi rapamicina com um doador de aciatal como um éster vinílico, um éster isopropenílico ou um anidrido em um solvente orgânico adequado.
BRPI0509852-1A 2004-04-14 2005-04-12 método para a preparação regioespecìfica dos derivados de 42-éster de rapamicina, preparação regioespecìfica do 42-éster de rapamicina, composição, produto, e, kit farmacêutico BRPI0509852A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56192604P 2004-04-14 2004-04-14
PCT/US2005/012266 WO2005105811A1 (en) 2004-04-14 2005-04-12 Regiospecific synthesis of rapamycin 42-ester derivatives

Publications (1)

Publication Number Publication Date
BRPI0509852A true BRPI0509852A (pt) 2007-10-23

Family

ID=34965235

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0509852-1A BRPI0509852A (pt) 2004-04-14 2005-04-12 método para a preparação regioespecìfica dos derivados de 42-éster de rapamicina, preparação regioespecìfica do 42-éster de rapamicina, composição, produto, e, kit farmacêutico

Country Status (23)

Country Link
US (1) US7268144B2 (pt)
EP (1) EP1737869A1 (pt)
JP (1) JP4224115B2 (pt)
KR (1) KR20070015544A (pt)
CN (1) CN1942476A (pt)
AR (1) AR049019A1 (pt)
AU (1) AU2005238431A1 (pt)
BR (1) BRPI0509852A (pt)
CA (1) CA2562952A1 (pt)
CL (1) CL2008000507A1 (pt)
CR (1) CR8646A (pt)
EC (1) ECSP066927A (pt)
GT (1) GT200500085A (pt)
IL (1) IL178315A0 (pt)
MX (1) MXPA06011881A (pt)
NO (1) NO20065090L (pt)
PA (1) PA8629901A1 (pt)
PE (1) PE20060253A1 (pt)
RU (1) RU2387657C2 (pt)
SG (1) SG152234A1 (pt)
TW (1) TW200536542A (pt)
UA (1) UA87492C2 (pt)
WO (1) WO2005105811A1 (pt)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
ES2313328T3 (es) * 2004-04-14 2009-03-01 Wyeth Procedimiento para la preparacion de 42-esteres de rapamicina y 32-esteres de fk-506 con acido dicarboxilico, precursores para conjugados de rapamicina y anticuerpos.
JP2007534337A (ja) * 2004-04-27 2007-11-29 ワイス ラパマイシン特異的メチラーゼを用いるラパマイシンの標識
SV2006002188A (es) * 2004-08-10 2006-03-15 Wyeth Corp Derivados de cci - 779 y metodos para su preparacion ref. am-101759salvo
EP1856130A1 (en) 2005-02-09 2007-11-21 Wyeth a Corporation of the State of Delaware Cci-779 polymorph and use thereof
WO2007056175A2 (en) * 2005-11-04 2007-05-18 Wyeth 41-methoxy isotope labeled rapamycin 42-ester
KR20080077618A (ko) * 2005-12-07 2008-08-25 와이어쓰 정제된 결정체 ｃｃｉ-779 의 제조 방법
RU2008120712A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Способы получения кристаллического рапамицина и определения кристалличности соединений рапамицина при помощи дифференциальной сканирующей калориметрии
RU2008120670A (ru) * 2005-12-07 2010-01-20 Вайет (Us) Масштабируемый способ получения 42-сложного эфира рапамицина из 42-сложного эфира рапамицина бороната
KR20080106225A (ko) * 2006-03-07 2008-12-04 와이어쓰 마크롤라이드 면역억제제의 수용성 폴리에틸렌 글리콜 콘쥬게이트를 제조하는 방법
US8425459B2 (en) 2006-11-20 2013-04-23 Lutonix, Inc. Medical device rapid drug releasing coatings comprising a therapeutic agent and a contrast agent
US9700704B2 (en) 2006-11-20 2017-07-11 Lutonix, Inc. Drug releasing coatings for balloon catheters
US20080276935A1 (en) 2006-11-20 2008-11-13 Lixiao Wang Treatment of asthma and chronic obstructive pulmonary disease with anti-proliferate and anti-inflammatory drugs
US8998846B2 (en) 2006-11-20 2015-04-07 Lutonix, Inc. Drug releasing coatings for balloon catheters
US8414525B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US8414526B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US9737640B2 (en) 2006-11-20 2017-08-22 Lutonix, Inc. Drug releasing coatings for medical devices
US8414910B2 (en) 2006-11-20 2013-04-09 Lutonix, Inc. Drug releasing coatings for medical devices
US20080175887A1 (en) 2006-11-20 2008-07-24 Lixiao Wang Treatment of Asthma and Chronic Obstructive Pulmonary Disease With Anti-proliferate and Anti-inflammatory Drugs
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
US20090253733A1 (en) * 2008-04-02 2009-10-08 Biointeractions, Ltd. Rapamycin carbonate esters
WO2009131631A1 (en) * 2008-04-14 2009-10-29 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
WO2010024898A2 (en) 2008-08-29 2010-03-04 Lutonix, Inc. Methods and apparatuses for coating balloon catheters
CN101676291B (zh) * 2008-09-18 2012-05-09 上海海和药物研究开发有限公司 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途
PT2365802T (pt) 2008-11-11 2017-11-14 Univ Texas Microcápsulas de rapamicina e utilização para o tratamento de cancro
IT1394309B1 (it) * 2009-05-22 2012-06-06 Poli Ind Chimica Spa Nuovo approccio chimico-enzimatico alla sintesi del pimecrolimus
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
EP2694520A1 (en) * 2011-04-01 2014-02-12 Sandoz AG Regioselective acylation of rapamycin at the c-42 position
US9408884B2 (en) * 2012-06-08 2016-08-09 Biotronik Ag Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
US10751450B2 (en) 2012-06-08 2020-08-25 Biotronik Ag Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
WO2014160328A1 (en) 2013-03-13 2014-10-02 The Board Of Regents Of The University Of Texas System Mtor inhibitors for prevention of intestinal polyp growth
WO2014145780A1 (en) * 2013-03-15 2014-09-18 Biosensors International Group, Ltd. Purification of rapamycin derivatives
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
CA3021645A1 (en) 2016-04-29 2017-11-02 Icahn School Of Medicine At Mount Sinai Targeting the innate immune system to induce long-term tolerance and to resolve macrophage accumulation in atherosclerosis
JP7185633B2 (ja) 2017-02-17 2022-12-07 トレベナ・インコーポレイテッド ７員アザ複素環を含有するデルタ－オピオイド受容体調節化合物、その使用方法及び製造方法
EP3848065B1 (en) 2017-05-15 2023-07-26 C. R. Bard, Inc. Medical device with drug-eluting coating and intermediate layer
CA3082831A1 (en) * 2017-11-20 2019-05-23 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobiologic composition
JP7262581B2 (ja) 2018-11-14 2023-04-21 ルトニックス，インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
JP7487228B2 (ja) 2019-04-08 2024-05-20 バード・ペリフェラル・バスキュラー・インコーポレーテッド 改質されたデバイス表面に薬物溶出コーティングを有する医療用デバイス
US20240100025A1 (en) * 2020-12-14 2024-03-28 Biotronik Ag Materials and Methods for Treating Viral and Other Medical Conditions
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
WO2023070605A1 (en) * 2021-10-29 2023-05-04 Trevena, Inc. Methods of preparing 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds
CN118027062B (zh) * 2023-11-03 2025-02-14 沈阳药科大学 一种雷帕霉素前药及其纳米制剂的制备和应用
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5210030A (en) * 1990-06-25 1993-05-11 Merck & Co., Inc. Process for selectively acylating immunomycin
PT98990A (pt) * 1990-09-19 1992-08-31 American Home Prod Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
US5233036A (en) 1990-10-16 1993-08-03 American Home Products Corporation Rapamycin alkoxyesters
US5100883A (en) 1991-04-08 1992-03-31 American Home Products Corporation Fluorinated esters of rapamycin
US5118678A (en) 1991-04-17 1992-06-02 American Home Products Corporation Carbamates of rapamycin
US5118677A (en) 1991-05-20 1992-06-02 American Home Products Corporation Amide esters of rapamycin
US5260300A (en) 1992-11-19 1993-11-09 American Home Products Corporation Rapamycin carbonate esters as immuno-suppressant agents
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5780462A (en) 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) * 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
CA2421485A1 (en) 2000-09-19 2002-03-28 Wyeth Water soluble rapamycin esters
AU2003254168A1 (en) 2002-07-30 2004-02-16 Wyeth Parenteral formulations containing a rapamycin hydroxyester
PT1658295E (pt) 2003-08-07 2007-09-25 Wyeth Corp Síntese regiosselectiva de cci-779
AU2004270154A1 (en) 2003-09-03 2005-03-17 Wyeth Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions containing the same
DK1701698T3 (da) 2004-01-08 2008-05-05 Wyeth Corp Direkte komprimerbart farmaceutisk præparat til oral indgivelse af CCI-779

Also Published As

Publication number Publication date
WO2005105811A1 (en) 2005-11-10
US7268144B2 (en) 2007-09-11
JP4224115B2 (ja) 2009-02-12
RU2387657C2 (ru) 2010-04-27
CL2008000507A1 (es) 2008-07-04
TW200536542A (en) 2005-11-16
JP2007532134A (ja) 2007-11-15
CR8646A (es) 2007-08-28
CN1942476A (zh) 2007-04-04
US20050234234A1 (en) 2005-10-20
PE20060253A1 (es) 2006-03-30
SG152234A1 (en) 2009-05-29
KR20070015544A (ko) 2007-02-05
UA87492C2 (en) 2009-07-27
EP1737869A1 (en) 2007-01-03
MXPA06011881A (es) 2006-12-14
NO20065090L (no) 2006-11-13
CA2562952A1 (en) 2005-11-10
AU2005238431A1 (en) 2005-11-10
PA8629901A1 (es) 2006-06-02
ECSP066927A (es) 2006-12-20
IL178315A0 (en) 2007-02-11
AR049019A1 (es) 2006-06-21
RU2006134014A (ru) 2008-05-20
GT200500085A (es) 2005-11-03

Similar Documents

Publication Publication Date Title
CR8646A (es) Sintesis regioespecifica de derivados de ester-42 de rapamicina
Chen et al. Secondary metabolites from higher fungi
Wang et al. Melophlins C− O, thirteen novel tetramic acids from the marine sponge Melophlus sarassinorum
Praveen et al. Bis (indolyl) methane alkaloids: isolation, bioactivity, and syntheses
Williams et al. Spirastrellolide A: revised structure, progress toward the relative configuration, and inhibition of protein phosphatase 2A
Tsukamoto et al. Aaptamine, an alkaloid from the sponge Aaptos suberitoides, functions as a proteasome inhibitor
Lee et al. Protuboxepins A and B and protubonines A and B from the marine-derived fungus Aspergillus sp. SF-5044
Popplewell et al. Colensolide A: A new nitrogenous bromophenol from the New Zealand marine red alga Osmundaria colensoi
CL2007002910A1 (es) Composicion farmaceutica que comprende compuestos derivados de anillos monociclicos, biciclicos o triciclicos, inhibidores de amidohidrolasa de acidos grasos; complejo que comprende al compuesto; y uso en el tratamiento de enfermedades tales como dol
Ancheeva et al. Expanding the metabolic profile of the fungus Chaetomium sp. through co‐culture with autoclaved Pseudomonas aeruginosa
CR20110314A (es) Compuestos orgánicos
JP2007532134A5 (pt)
Fuwa et al. Total Synthesis, Stereochemical Reassignment, and Biological Evaluation of (−)‐Lyngbyaloside B
CL2012000707A1 (es) Compuestos derivados de [5-(pirrolo[1,2-c][1.2.3]triazin-7-il)tetrahidrofuran-2-il]metanol; composición farmacéutica; y su uso para el tratamiento de la hepatitis c.
NI200700222A (es) N-hydroxiamidas omega-sustituidas con grupos triciclicos como inhibidores de histona de desacetilasa, su preparación y su uso en formulaciones farmacéuticas.
WO2009070645A8 (en) Indoles, derivatives, and analogs thereof and uses thereof
Wang et al. Dimeric octaketide spiroketals from the jellyfish-derived fungus Paecilomyces variotii J08NF-1
Park et al. Glionitrin B, a cancer invasion inhibitory diketopiperazine produced by microbial coculture
EP2546256A3 (en) Process for the synthesis of intermediates compounds useful for the preparation of E1 activity activating enzyme inhibitors
Suzuki et al. Isolation of spirastrellolides A and B from a marine sponge Epipolasis sp. and their cytotoxic activities
PA8630001A1 (es) Prolina cci-779, produccion y usos de la misma, y sintesis enzimatica de dos etapas de prolina cci-779 y cci-779
WO2008006113A3 (en) Novel belactosin derivatives as therapeutic agents/biological probes and their synthesis
Pettit et al. Antineoplastic agents. 542. Isolation and structure of sesterstatin 6 from the Indian Ocean sponge Hyrtios erecta
Tran-Cong et al. Induction of cryptic metabolites of the endophytic fungus Trichocladium sp. through OSMAC and co-cultivation
Lee et al. Relative configurational assignment of 4-hydroxyprorocentrolide and prorocentrolide C isolated from a benthic dinoflagellate (Prorocentrum lima)

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.

B15K Others concerning applications: alteration of classification

Ipc: C07D 498/18 (2006.01), C12P 17/18 (2006.01)